NASDAQ:RUBY Rubius Therapeutics (RUBY) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free RUBY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.06▼$0.0650-Day Range$0.02▼$0.0652-Week Range$0.00▼$0.38Volume755,858 shsAverage Volume1.15 million shsMarket Capitalization$5.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisInsider TradesSocial MediaSustainabilityStock AnalysisInsider TradesSocial MediaSustainability Get Rubius Therapeutics alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Rubius Therapeutics Stock (NASDAQ:RUBY)Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. RUBY Stock News HeadlinesApril 26, 2024 | yahoo.com‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)March 11, 2024 | bizjournals.comVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'April 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.November 5, 2023 | morningstar.comRubius Therapeutics Inc RUBYAugust 2, 2023 | uk.finance.yahoo.comRUBY - Rubius Therapeutics, Inc.July 25, 2023 | morningstar.comNorth American Morning Briefing: Alphabet, -2-March 2, 2023 | finance.yahoo.comRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On AlternativesFebruary 14, 2023 | marketwatch.comThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?April 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 14, 2023 | msn.comWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?January 25, 2023 | yahoo.comThe Wrap: Ruby's moving to Congress Street, launching new French conceptJanuary 12, 2023 | mirror.co.ukRuby Wax sparks concern from fans after posting video from hospital bedJanuary 12, 2023 | dailymail.co.ukRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookNovember 18, 2022 | finance.yahoo.comFormer Rubius CEO jumps to another Flagship spinoutNovember 4, 2022 | finance.yahoo.comRubius Therapeutics lays off most of its staff, explores saleNovember 3, 2022 | finance.yahoo.comRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic AlternativesNovember 2, 2022 | seekingalpha.comRubius stock falls over 5% after hours on strategic review, more job cutsNovember 2, 2022 | finance.yahoo.comRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesOctober 28, 2022 | finance.yahoo.comRubius Therapeutics, Inc. (RUBY)October 10, 2022 | reuters.comRubius Therapeutics IncSeptember 19, 2022 | bizjournals.comFlagship-backed Vesalius lays off 43%September 19, 2022 | finance.yahoo.comRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 14, 2022 | bizjournals.comRubius Therapeutics lays off 75% of staff, looks to sell Smithfield facilitySeptember 13, 2022 | finance.yahoo.comRubius Therapeutics scraps platform, lays off 160September 13, 2022 | finance.yahoo.comRubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer AssetsSeptember 13, 2022 | seekingalpha.comRubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforceSeptember 13, 2022 | nasdaq.comRubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick FactsSee More Headlines Receive RUBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RUBY CUSIPN/A CIK1709401 Webwww.rubiustx.com Phone(508) 543-1720FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.34Miscellaneous Outstanding Shares90,480,000Free Float85,687,000Market Cap$5.16 million OptionableNot Optionable Beta2.59 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Laurence A. Turka M.D. (Age 66)Chief Scientific Officer and Head of Research & Translational Medicine Comp: $626.55kMr. Craig R. Jalbert CIRA (Age 62)President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director Ms. Marissa HanifyDirector of Corporate CommunicationsKey CompetitorsPalisade BioNASDAQ:PALIFresh Tracks TherapeuticsNASDAQ:FRTXFinch Therapeutics GroupNASDAQ:FNCHChromocell TherapeuticsNYSE:CHROTRACON PharmaceuticalsNASDAQ:TCONView All Competitors RUBY Stock Analysis - Frequently Asked Questions How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. During the same quarter last year, the firm posted ($0.51) EPS. What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO? 12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM). When did Rubius Therapeutics IPO? Rubius Therapeutics (RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO. This page (NASDAQ:RUBY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
